NICE recommends new drug for ulcerative colitis that could benefit 25,000 patients
Etrasimod will be offered to patients aged over 16 years, who have had an inadequate response, lost response or were intolerant to either conventional therapy or biological treatment for moderately to severely active ulcerative colitis.…